Cefcanel daloxate

Drug Profile

Cefcanel daloxate

Alternative Names: KY 109

Latest Information Update: 07 Apr 1999

Price : $50

At a glance

  • Originator Kyoto Pharmaceutical Industries
  • Developer AstraZeneca
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Otitis media; Respiratory tract infections

Most Recent Events

  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
  • 04 Jun 1998 Discontinued-III for Respiratory tract infections in Sweden (PO)
  • 04 Jun 1998 Discontinued-III for Otitis media in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top